|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatic schwannoma:Imaging findings on CT,MRI and contrast-enhanced ultrasonography显示文摘A primary benign schwannoma of the liver is extremely rare and is difficult to preoperatively discriminate from a malignant tumor.We compared the imaging and pathological findings,and examined the possibility of preoperatively diagnosing a benign liver schwannoma.A 72-year-old woman was admitted to our hospital because of a 4.6-cm mass in the liver.A malignant tumor was suspected,and a right hepatectomy was performed.After this,the diagnosis of a primary benign schwannoma of the liver was made through pathological examination.Contrast-enhanced ultrasonography(CEUS) with Sonazoid showed minute blood flows into the septum and solid areas of the tumor in the vascular phase;most likely due to increased arterial flow associated with infiltration of chronic inflammatory cells.In the postvascular phase,CEUS showed contrast defect of cystic areas and delayed enhancement of solid areas;most likely due to aggregation of siderophores.Because discriminating between a benign and malignant schwannoma of the liver is difficult,surgery is generally recommended.However,the two key findings from CEUS may be useful in discriminating ancient schwannoma by recognizing the hemorrhage involved in the secondary degeneration and aggregation of siderophores. | Yu Ota Kazunobu Aso Kenji Watanabe Takahiro Einama Koji Imai Hidenori Karasaki Ryuji Sudo Yosui Tamaki Mituyoshi Okada Yosihiko Tokusashi Toru Kono Naoyuki Miyokawa Masakazu Haneda Masahiko Taniguchi Hiroyuki Furukawa | 2012 | World Journal of Gastroenterology2012，18，35： | 11 |
| 2 | Medical management of gastric cancer:A 2014 update显示文摘Gastric cancer represents a serious health problem on a global scale. It is the second leading cause of cancer-related death worldwide. Novel therapeutic targets are desperately needed because the meager improvement in the cure rate of about 10% realized by adjunctive treatments to surgery is unacceptable as > 50% patients with localized gastric cancer succumb to their disease. Either postoperative chemoradiotherapy(United States),pre-and post-operative chemotherapy(Europe),and adjuvant chemotherapy after a D2 resection(Asia) can all be regarded as standards of care in the localized gastric cancer management. In metastatic disease the addition of trastuzumab to chemotherapy is standard of care in Her2 positive disease. In the HER2 negative population,the treatments remain limited.In the first line setting,the standard of care is a combination of fluoropyrimidine and platinum containing chemotherapy,with or without epirubicin or docetaxel.The results of targeted therapy trials have by and large been disappointing,but none of these trials looked at an appropriately enriched population.Finally there is a meager overall survival benefit in treating patients with metastatic disease in the second line setting,with either irinotecan,docetaxel or ramucirumab however none of these drugs have been compared head to head in a well-powered randomized controlled trial. | Elena Elimova Hironori Shiozaki Roopma Wadhwa Kazuki Sudo Qiongrong Chen Jeannelyn S Estrella Mariela A Blum Brian Badgwell Prajnan Das Shumei Song Jaffer A Ajani | 2014 | World Journal of Gastroenterology2014，20，38： | 10 |
| 3 | S-1 in the treatment of pancreatic cancer显示文摘S-1 is an oral 5-fluorouracil(5-FU) prodrug,which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase,the key enzyme of 5-FU catabolism.Recently,two important studies on the clinical use of S-1 for pancreatic cancer have been reported from Japan.In the first study(GEST study),S-1 demonstrated non-inferiority to gemcitabine(GEM) in overall survival(OS) for metastatic or locally advanced pancreatic cancer,but combination chemotherapy with GEM and S-1 did not show superiority to GEM in OS.In the second study(JASPAC-01 study),S-1 showed superiority to adjuvant chemotherapy with GEM in OS in patients with resected pancreatic cancer.In addition to GEM,S-1 is now regarded as the key drug in the management of pancreatic cancer in Japan.To date,many studies have investigated the effectiveness of S-1 in various settings,such as first-line chemotherapy for metastatic or locally advanced pancreatic cancer,second-line chemotherapy after GEM failure,and chemoradiotherapy for locally advanced disease.In this review,we focus on recent clinical trials of S-1-based chemotherapy for advanced pancreatic cancer. | Kentaro Sudo Kazuyoshi Nakamura Taketo Yamaguchi | 2014 | World Journal of Gastroenterology2014，20，41： | 9 |
| 4 | Evolution of gastric surgery techniques and outcomes显示文摘Surgical management of gastric cancer improves survival.However,for some time,surgeons have had diverse opinions about the extent of gastrectomy.Researchers have conducted many clinical studies,making slow but steady progress in determining the optimal surgical approach.The extent of lymph node dissection has been one of the major issues in surgery for gastric cancer.Many trials demonstrated that D2 dissection resulted in greater morbidity and mortality than D1 dissection.However,long-term outcomes demonstrated that D2 dissection resulted in longer survival than D1 dissection.In 2004,the Japan Clinical Oncology Group reported a pivotal trial which was performed to determine whether para-aortic lymph node dissection combined with D2 dissection was superior to D2 dissection alone and found no benefit of the additional surgery.Gastrectomy with pancreatectomy,splenectomy,and bursectomy was initially recommended as part of the D2 dissection.Now,pancreas-preserving total gastrectomy with D2 dissection is standard,and ongoing trials are addressing the role of splenectomy.Furthermore,the feasibility and safety of laparoscopic gastrectomy are well established.Survival and quality of life are increasingly recognized as the most important endpoints.In this review,we present perspectives on surgical techniques and important trials of these techniques in gastric cancer patients. | Hironori Shiozaki Yusuke Shimodaira Elena Elimova Roopma Wadhwa Kazuki Sudo Kazuto Harada Jeannelyn S.Estrella Prajnan Das Brian Badgwell Jaffer A.Ajani | 2016 | Chinese Journal of Cancer2016，35，8： | 9 |
| 5 | miR-122-5p as a novel biomarker for alpha-fetoproteinproducing gastric cancer显示文摘AIM To investigate the clinical utility of alpha-fetoprotein(AFP)-producing gastric cancer(AFPGC)-specific microRNA(mi RNA)for monitoring and prognostic prediction of patients.METHODS We performed a comprehensive miRNA array-based approach to compare miRNA expression levels between AFP-positive and AFP-negative cells in three patients with primary AFPGC.We next examined the expression levels of the selected miRNAs in five AFPGC and ten non-AFPGC tissue samples by quantitative reverse transcription-polymerase chain reaction to validate their utility.We also investigated the expression levels of the selected miRNA not only in tissue but also in plasma samples.Moreover,we investigated the relationship between plasma AFP levels and plasma selected miRNA expression levels,and also investigated the correlation of the selected miRNA expression levels and malignant potential.RESULTS Among the five miRNAs selected from the miRNA array results,the expression levels of miR-122-5p were significantly higher in the AFPGC patients than in the non-AFPGC patients(P<0.05).In tissue samples,mi R-122-5p expression level tended to be lower in the non-AFPGC tissue than the normal gastric mucosa.Conversely,in the AFPGC tissue,miR-122-5p expression level was significantly higher in the AFPGC tissue than both the normal gastric mucosa and the nonAFPGC tissue samples(P<0.05).Plasma mi R-122-5p expression levels were also significantly higher in the AFPGC patients than the health volunteers and the nonAFPGC patients(P<0.05)and were strongly correlated with plasma AFP levels(r=0.7975,P<0.0001).Moreover,the correlation of miR-122-5p expression in tissue samples with malignant potential was stronger than that of plasma AFP level in the AFPGC patients.In contrast,no correlation was found between mi R-122-5p expression levels and liver metastasis in the non-AFPGC patients.CONCLUSION miR-122-5p might be a useful biomarker for early detection and disease monitoring in AFPGC. | Suguru Maruyama Shinji Furuya Kensuke Shiraishi Hiroki Shimizu Hidenori Akaike Naohiro Hosomura Yoshihiko Kawaguchi Hidetake Amemiya Hiromichi Kawaida Makoto Sudo Shingo Inoue Hiroshi Kono Daisuke Ichikawa | 2018 | World Journal of Gastrointestinal Oncology2018，10，10： | 6 |
| 6 | ICRF Heated Long-Pulse Plasma Discharges in LHD显示文摘A long-pulse plasma discharge for more than 30 min.was achieved on the LargeHelical Device(LHD).A plasma of n_e=0.8×10^(19)m^(-3)and T_(iO)=2.0 keV was sustained withP_(ICH)=0.52 MW,P_(ECH)=0.1 MW and averaged P_(NBI)=0.067 MW.Total injected heatingenergy was 1.3 GJ,which was a quarter of the prepared RF heating energy.One of the keys to thesuccess of the experiment was a dispersion of the local plasma heat load to divertors,accomplishedby shifting the magnetic axis inward and outward. | R. KUMAZAWA T. SEKI T. MUTOH K. SAITO T. WATARI Y. NAKAMURA M. SAKAMOTO T. WATANABE S. KUBO T. SHIMOZUMA Y. YOSHIMURA H. IGAMI Y. TAKEIRI Y. OKA K. TSUMORI M. OSAKABE K. IKEDA K. NAGAOKA O. KANEKO J. MIYAZAWA S. MORITA K. NARIHARA M. SHOJI S. MASUZAKI M. GOTO T. MORISAKI B. J. PETERSON K. SATO T. TOKUZAWA N. ASHIKAWA K. NISHIMURA H. FUNABA H. CHIKARAISHI T. NOTAKE Y. TORII H. OKADA M. ICHIMURA H. HIGAKI Y. TAKASE H. KASAHARA F. SHIMPO G.NOMURA C.TAKAHASHI M.YOKOTA A. KATO 赵燕平 J. S. YOON J. G. KWAK H. YAMADA K. KAWAHATA N. OHYABU K. IDA Y. NAGAYAMA N. NODA A. KOMORI S. SUDO O. MOTOJIMA | 2006 | Plasma Science and Technology2006，8，1： | 4 |
| 7 | Gemcitabine-Based Adjuvant Chemotherapy Improves Survival After Aggressive Surgery for Hilar Cholangiocarcinoma显示文摘 | Yoshiaki Murakami Kenichiro Uemura Takeshi Sudo Yasuo Hayashidani Yasushi Hashimoto Hiroaki Nakamura Akira Nakashima Taijiro Sueda | 2009 | Journal of Gastrointestinal Surgery2009，，8： | 2 |
| 8 | Clinical significance of the expression of long non-coding RNA HOTAIRin primary hepatocellular carcinoma显示文摘 | Masahisa Ishibashi Ryunosuke Kogo Kohei Shibata Genta Sawada Yusuke Takahashi Junji Kurashige Sayuri Akiyoshi Shin Sasaki Takeshi Iwaya Tomoya Sudo Keishi Sugimachi Koshi Mimori Go Wakabayashi Masaki Mori | 2013 | Oncology Reports2013，，3： | 2 |
| 9 | 黄金鲈与伊犁鲈杂交后代在气提泵循环水养殖系统中生长分析显示文摘研究通过黄金鲈(Perca flavescens)雌鱼与伊犁鲈(Perca schrenki)雄鱼进行杂交,以期加快鲈鱼的生长速度,推迟其性成熟和提高上市规格。为减少饲养环境条件和人为管理差异造成生长试验误差,研究采用试验鱼同池混养的方法进行生长比较。在气提泵循环水养殖系统中,经690 d的生长比较试验。结果表明:杂交鲈体重增长比黄金鲈快33.91%;杂交鲈的性腺发育被推迟或性腺发育不良;黄金鲈和杂交鲈的成活率分别为87.50%和82.08%,二者在成活率上无显著差异(P=0.29)。杂交鲈适宜在高密度循环水养殖条件下生长,杂交优势较为显著,可以取代黄金鲈进行集约化养殖生产。 | 刘青华 蔡明园 王佳 Naomi Sudo Cheryl Goudie | 2009 | 渔业现代化2009，36，4： | 2 |
| 10 | 钢帘线钢丝索氏体化处理条件对拉拔期间中心裂纹的影响显示文摘弄清楚导致拉拔期间“中心裂纹”的内部缺陷,要比弄清表面缺陷如过热和划痕困难,因此,当钢丝拉断且操作中断时,仅认为是中心裂纹造成的。钢丝如果没拉断,内部裂纹像一个箭头状遗留在产品内(照片1)。 | Masatake Tomita Takashi Tsukamoto Chuzo Sudo Terutaka Tsumura 孙留根 | 1993 | 金属制品1993，，A11： | 2 |
| 11 | Phase II Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer显示文摘 | Kentaro Sudo Taketo Yamaguchi Takeshi Ishihara Kazuyoshi Nakamura Taro Hara Tadamichi Denda Katsunobu Tawada Toshiyuki Imagumbai Hitoshi Araki Mitsuhiro Sakai Kazuo Hatano Hiroyuki Kawakami Takashi Uno Hisao Ito Osamu Yokosuka | 2011 | International Journal of Radiation Oncology Biology Physics2011，，1： | 2 |
| 12 | Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathologicalsignificance显示文摘 | Yojiro Hashiguchi Naohiro Nishida Koshi Mimori Tomoya Sudo Fumiaki Tanaka Kohei Shibata Hideshi Ishii Hidetaka Mochizuki Kazuo Hase Yuichiro Doki Masaki Mori | 2012 | International Journal of Oncology2012，，5： | 2 |
| 13 | Cilostazol,a selective type III phosphodiesterase inhibitor,decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats显示文摘 | Tani T Uehara K Sudo T | 2000 | Atherosclerosis2000，152，： | 2 |
| 14 | Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival After Aggressive Surgical Resection for Advanced Biliary Carcinoma显示文摘 | Yoshiaki Murakami Kenichiro Uemura Takeshi Sudo Yasuo Hayashidani Yasushi Hashimoto Hiroyuki Nakamura Akira Nakashima Taijiro Sueda | 2009 | Annals of Surgery2009，，6： | 2 |
| 15 | 亚洲电炉工艺的现状及发展趋势显示文摘1997年亚洲电沪钢产量达到9700万t,占粗钢总产量的31%,电炉工艺在钢铁生产中的地位日益重要。本文描述亚洲电炉工艺现状及发展前景,重点论述目前在亚洲处于领先地位的日本电炉工艺水平及技术发展趋势,并对亚洲与世界范围内电炉工艺的发展方向进行了展望。 | Sudo,F 陈亮 | 2000 | 世界钢铁2000，，2： | 2 |
| 16 | Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer显示文摘 | Kentaro Sudo Takeshi Ishihara Nobuto Hirata Fumiaki Ozawa Tadashi Ohshima Ryosaku Azemoto Kenji Shimura Takeshi Nihei Takayoshi Nishino Akihiko Nakagawa Kazuyoshi Nakamura Taro Hara Motohisa Tada Rintaro Mikata Katsunobu Tawada Osamu Yokosuka So Nakaji Ta | 2014 | Cancer Chemotherapy and Pharmacology2014，，2： | 2 |
| 17 | Experimental Study of Differences in DNB Heat Flux between Upflow and Downflow in Vertical Rectangular Channel显示文摘 | Sudo Y | 1992 | Journal of Nuclear Science and Technology1992，22，8： | 2 |
| 18 | Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis显示文摘 | S. Fushida J. Kinoshita M. Kaji Y. Hirono F. Goda Y. Yagi K. Oyama Y. Sudo Y. Watanabe T. Fujimura | 2013 | Cancer Chemotherapy and Pharmacology2013，，5： | 2 |
| 19 | The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers显示文摘 | Mimori K Nagahara H Sudo T | 2006 | J Surg Oncol2006，93，1： | 1 |
| 20 | Systemically injected exo- somes targeted to EGFR deliver antitumor microRNA to breast cancer cells显示文摘 | Ohno SI Takanashi M Sudo K | 2013 | Mol Ther2013，21，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员